Run four tests on any review. Ask who is paid when a reader clicks, whether a clinical number was borrowed from a trial of an approved product, whether the word registered has quietly replaced approved, and whether the price shown is the starting dose. Most semaglutide roundups fail at least two of the four.
The claim the FDA treats as a warning sign
The single most repeated line in this market is that a compounded preparation is the same as the brand product. FDA lists that exact claim among its telehealth warning signs for consumers, alongside deep discounts, medicine that looks different from what was pictured, packaging that arrives damaged or without instructions, and no licensed clinician available to answer questions after delivery.
The agency has been more specific about semaglutide than about the class in general. It has stated that salt forms sold by some compounders, including semaglutide sodium and semaglutide acetate, are different active ingredients from the one in approved products, that it lacks information on whether those salts share the same chemical and pharmacologic properties, and that it is not aware of a lawful basis for using them in compounding. A review that treats every semaglutide as interchangeable has skipped past a distinction the regulator has already drawn.
Trial numbers travel further than the products they came from
Roughly 15 percent mean weight change is the figure that circulates most widely. It comes from the registration trial of once-weekly semaglutide 2.4 mg over 68 weeks, run with lifestyle intervention in a defined population. Related trials tell different parts of the story: one found continued treatment held and extended the loss while a switch to placebo reversed part of it, and the extension of the registration trial reported that participants regained about two thirds of their lost weight within a year of stopping.
None of those results attach to a seller. When a provider page or a roundup places a trial percentage next to a product it dispenses, the honest version names the trial, the dose, the duration, and the product studied. A comparative cohort study of semaglutide against tirzepatide reported greater average reduction with tirzepatide, which is useful context about molecules and says nothing about which website to buy from.
Registered, licensed, and approved are three different words
Reviews use them as if they escalate along one scale. They do not. A pharmacy holds a state license to operate. An outsourcing facility registers with FDA, which is a filing status rather than a judgment about any product it makes. Approval is a decision about a specific drug, made after review of safety, effectiveness, and manufacturing quality. Compounded semaglutide has none of that third thing, and no amount of the first two substitutes for it.
Ratings measure the first month, not the twelfth
Public reviews of telehealth weight programs cluster in the first weeks, when the experience being rated is signup speed, shipping, and the starting dose. The problems that decide whether treatment continues arrive later: a dose step that is not tolerated, a refill that lands late, a price that moves when the strength moves, a message about nausea that waits three days for a reply. A rating average built almost entirely from week-two experiences cannot see any of that.
Going past the rating means reading what each provider states on its own pages. Services such as Henry Meds, Mochi, and HealthRX describe how they handle semaglutide titration and refills in writing, which a reader can set against the labeled schedule and the trial figures rather than against a star count. Those pages hold still long enough to check, where an average built from week-two impressions keeps shifting.
Sample shape matters as much as sample size. Programs that solicit feedback right after delivery collect a different population than programs that survey at six months, and neither number is comparable to the other even when both are honest.
Tracing a ranking back to its funding
Affiliate arrangements are legal and common, and disclosure is the test rather than existence. Check whether the same set of names appears in the same order across a dozen sites, whether the disclosure sits above the list or below the footer, and whether any provider named as a runner-up is described in enough detail to show someone looked at it. Reading each provider’s own pricing and pathway pages, whether that is Ro, Mochi, Henry Meds, formblends.com, or NovoCare Pharmacy, produces something checkable in a way that an ordered list does not.
| Claim as written | What would verify it | What it usually rests on |
|---|---|---|
| “Same active ingredient as the brand” | An approved product label naming that ingredient and form | A supplier certificate, sometimes for a salt form |
| “Patients lose 15 percent” | Trial name, dose, duration, and the product studied | A trial of the approved 2.4 mg injection |
| “FDA registered pharmacy” | Registration status, which covers the facility only | A filing, not a product review |
| “Doctor supervised” | Clinician name and state license lookup | An intake form reviewed at unspecified depth |
| “From $X per month” | The figure at maintenance strength, in writing | The lowest step of the titration ladder |
| “Rated best for 2026” | Stated method, sample, and payment disclosure | Affiliate commission ordering |
Frequently asked questions
Does an affiliate link make a review worthless?
No, but it changes what the ordering means. Commission rates differ by provider, so a ranked list can be sorted by payout without a single false sentence in it. Treat the ordering as commercial and the underlying facts as testable, then verify the facts that would actually change your decision.
How can a weight loss percentage be checked quickly?
Search the trial name on PubMed and read the abstract. It will state the dose, the duration, the comparator, and the population. If the review does not name a trial at all, the number is unsourced, and a provider quoting it about its own compounded preparation is quoting research that studied something else.
Are negative reviews more reliable than positive ones?
Not inherently. Complaints skew toward billing and shipping because those produce a clear grievance, while clinical experience produces ambiguity that people write about less. Both directions are useful for spotting patterns and neither is useful for estimating average outcomes across a program’s whole population.
What about before and after photographs?
They carry no verifiable information about a provider. There is no way for a reader to confirm the medication, the dose, the timeframe, or whether the same person appears in both frames. Published trial results with defined endpoints do the work photographs pretend to do.
Is a program worse for using compounded semaglutide?
Not automatically. Compounding operates within a legal framework, and FDA describes it as appropriate where an approved product cannot meet a patient’s medical need. The failure is not the pathway. It is a page that presents the compounded preparation as equivalent to an approved product when the regulator says otherwise.
Sources
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, Human Drug Compounding Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- FDA, BeSafeRx: Your Source for Online Pharmacy Information. https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
- DailyMed, WEGOVY (semaglutide) injection and tablets prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). https://pubmed.ncbi.nlm.nih.gov/33567185/
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). https://pubmed.ncbi.nlm.nih.gov/33755728/
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. https://pubmed.ncbi.nlm.nih.gov/35441470/
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/
- Navigating compounded semaglutide: what health care providers need to know. https://pubmed.ncbi.nlm.nih.gov/40966636/
